Skip to main content
. Author manuscript; available in PMC: 2014 Sep 11.
Published in final edited form as: Surg Neurol. 2008 May;69(5):441–446. doi: 10.1016/j.surneu.2007.12.016

Table 2. Clinical Outcomes for Medical and Endoscopic Treatment.

Comparison of safety and clinical outcomes between medical and endoscopic cohorts. GCS decline is defined as a drop in GCS of 2 or greater points during the first 24 hours of hospitalization. NIHSS decline is defined as a drop in NIHSS by 4 or greater points during the first 24 hours of hospitalization. The % mean hematoma reduction is defined as the mean reduction in hematoma size between the pre and post operative CT scans. Data from a single patient in the surgical group who experienced massive hematoma expansion before endoscopy was not included in this analysis. Hematoma enlargement of >33% was required to meet criteria for rebleed/expansion.

Medical Endoscopic
Admit GCS 11+/−2 7 +/−1
% with GCS decline 0 40%
Mean admit NIHSS 21+/−6 25+/−7
30 day NIHSS 18+/−11 18+/−8
% with NIHSS decline 25% 20%
% mRS <=2 at day 90 0 % 0 %
Mean mRS at day 90 4.5 +/−1 4.6 +/−1
Mean BI at day 90 25 +/−47 8 +/−18
% mean ICH volume change + 78%+/−142 -80% +/−13
% rebleed or expansion 25% 20%
90 day mortality 50% 20%

GCS = Glasgow Coma Scale, NIHSS = National Institute of Heath Stroke Scale, mRS = modified Rankin Score, BI = Barthel Index.